Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30073534 | 1.00 | KMT2A (0.58) | KMT2AL3MBTL1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4893361 | 0.85 | KMT2A (0.60) | KMT2AL3MBTL1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL12260740 | 0.85 | KMT2A (0.60) | KMT2AL3MBTL1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL2378215 | 0.84 | KMT2A (0.75) | KMT2AL3MBTL1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4462435 | 0.81 | KMT2A (0.61) | KMT2AL3MBTL1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17749718 | 0.80 | SMN1; SMN2 (0.56) | KMT2AL3MBTL1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL30073335 | 0.80 | SMN1; SMN2 (0.56) | KMT2AL3MBTL1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10578175 | 0.80 | SMN1; SMN2 (0.55) | KMT2ASMN1; SMN2KDM4EALDH1A1GAA | |
| SCHEMBL31172456 | 0.80 | SMN1; SMN2 (0.55) | KMT2ASMN1; SMN2KDM4EALDH1A1GAA | |
| SCHEMBL15653095 | 0.78 | SMN1; SMN2 (0.72) | KMT2AL3MBTL1SMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218375-B1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3218375-B1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-10183009-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-10183009-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3218375-A1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | Genentech, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016077378-A1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016077378-A1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183009-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRPF3 | KMT2A 126/4885L3MBTL1 2782/4885SMN1; SMN2 1340/4885 |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRPF3 | KMT2A 126/4885L3MBTL1 2782/4885SMN1; SMN2 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.